The fund underperformed the S&P 500 in Q1 2026 but highlighted Tempus AI as a new position amid healthcare tech growth.
Aristotle Capital Management’s Core Equity Fund reported a -4.45% total return in Q1 2026, trailing the S&P 500’s -4.33% decline. The underperformance was attributed to allocation effects, though security selection contributed positively. The fund focuses on companies with secular tailwinds or strong product cycles amid broader market weakness.
Tempus AI (NASDAQ:TEM), a healthcare technology firm specializing in AI-driven precision medicine, was added to the fund’s holdings. TEM closed at $45.90 on May 13, 2026, with a one-month return of -14.86% and a 52-week loss of 25.98%. The company holds a market capitalization of $8.31 billion. The fund cited TEM’s long-term potential in its Q1 investor letter.